Zinplava (bezlotoxumab)

Covers a single 10 mg/kg IV dose of Zinplava (bezlotoxumab) to reduce CDI recurrence in adults and pediatric patients ≥1 year who are receiving antibacterial treatment and are at high risk for recurrence; excluded are patients <1 year, those not on antibacterial therapy, prior bezlotoxumab recipients, and repeat dosing (safety/efficacy not studied). Key requirements: documentation of CDI diagnosis, current antibacterial treatment, age ≥1, evidence of high-risk for recurrence, no prior bezlotoxumab, and an administration record showing a single 10 mg/kg IV infusion over 60 minutes.

"Zinplava is indicated to reduce recurrence of Clostridium difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI a..."

Sign up to see full coverage criteria, indications, and limitations.